Navigation Links
Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Date:4/24/2008

PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company and participate in a discussion moderated by Morgan Stanley representatives on Wednesday, April 30, 2008 at 3:40 PM (ET) in the Plaza Ballroom.

To access a simultaneous webcast of Mr. Price's overview and discussion via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation, if any, will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
2. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
3. Pharmasset Receives $10 Million of Working Capital
4. Pharmasset Appoints Herbert J. Conrad as a Director
5. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
6. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Pharmasset Appoints Michael Rogers as Chief Development Officer
10. Pharmasset to Present at Three Investor Conferences in November 2007
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... KBioBox is pleased to announce ... extended GUIDE-Seq ananlysis. KBioBox has adapted their core technology and direct alignment algorithms ... easy to understand reports, extended indel analysis, and translocation analysis. , “The extended ...
(Date:8/21/2017)... ... August 21, 2017 , ... Boston Strategic ... experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide ... US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP ...
(Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance Chief Research Analyst, ... research update on Aytu Bioscience and cited promising increases in the prescription rates ... rates for Natesto® have more than doubled since March of this year and ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science are often thought of ... one might think. A Mesh Is Also a Snare, a group exhibition presented ... Center’s Esther Klein Gallery (EKG) on August 17 and run through September 30. An ...
Breaking Biology Technology:
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):